文献速递分子诊断临床血液与体液

临床决策支持树可优化嗜吞噬细胞无形体核酸检测利用

Clinical Decision Support Trees Can Help Optimize Utilization of Anaplasma phagocytophilum Nucleic Acid Amplification Testing.
PubMed 文献 · J Clin Microbiol · 2021-08-18

该回顾性队列研究基于12.5年成人AP核酸检测及邻近血常规和肝功能数据,构建决策树识别阴性患者集群。主要发现血小板>177×10^3/μl且年龄<48岁者AP核酸检测阴性(204/1204,17%,P<0.05), Chart审查亚组中血小板>188×10^3/μl且无发热寒战者亦阴性(58/402,14%,P<0.05)。决策树有望减少不必要的AP检测。

要点

  • 血小板>177×10^3/μl且年龄<48岁者AP核酸检测阴性。
  • 血小板>188×10^3/μl且无发热寒战者AP核酸检测阴性。
  • 决策树利用常规临床和实验室数据辅助检测决策。

核心结论

  • 基于血小板计数、年龄及发热寒战症状的决策树可识别AP核酸检测阴性患者,减少不必要检测。

研究设计与样本

  • 回顾性队列研究,构建12.5年成人AP核酸检测及邻近血常规和肝功能数据集(n=1204)。
  • 另建匹配阴性对照的亚组数据集(n=402)并进行病历审查。

主要发现

  • 137/1204(11%)患者AP核酸检测阳性。
  • 实验室数据集:血小板>177×10^3/μl且年龄<48岁者AP核酸检测阴性(204/1204,17%,P<0.05)。
  • 病历审查亚组:血小板>188×10^3/μl且无发热或寒战者AP核酸检测阴性(58/402,14%,P<0.05)。

关键数值与推荐

  • 血小板>177×10^3/μl且年龄<48岁提示AP核酸检测阴性。
  • 血小板>188×10^3/μl且无发热或寒战提示AP核酸检测阴性。

临床怎么用

  • 可利用常规血常规和临床信息(年龄、发热寒战)初步评估AP核酸检测必要性,减少低风险患者检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplasmosis, a tick-borne illness caused by Anaplasma phagocytophilum (AP), presents with nonspecific clinical symptoms, including fever and headache, and is often accompanied by laboratory abnormalities of leukopenia, thrombocytopenia, and mildly elevated liver function tests (LFTs). Laboratory confirmation of acute infection occurs with nucleic acid amplification testing (NAAT). This retrospective cohort study aimed to develop a clinical decision support algorithm to aid in decision-making about test ordering. A data set was constructed with AP NAAT results and time-adjacent complete blood count and LFT results for adult patients tested for AP in a 12.5-year period. A second, smaller data set matched each patient with a positive AP NAAT to two patients with negative tests. Chart review for clinical symptoms was performed on this smaller data set. A decision tree algorithm was deployed to identify patient clusters with negative AP NAAT results. A total of 137/1,204 (11%) patients tested positive by NAAT for AP. In the larger, laboratory-only data set (n = 1,204), patients with a platelet count of >177 × 103/μl and age of <48 years had a negative AP NAAT (204/1,204, 17%, P < 0.05). In the smaller, cohorted data set with chart review (n = 402), patients with a platelet count of >188 × 103/μl and no fever or chills also did not have positive AP NAAT (58/402, 14%, P < 0.05). We generated two decision trees that can help determine the utility of AP NAAT using readily available clinical and laboratory data. These have the potential to significantly reduce unnecessary AP testing.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Hamilton R, Pandora TR, Parsonnet J, et al. Clinical Decision Support Trees Can Help Optimize Utilization of Anaplasma phagocytophilum Nucleic Acid Amplification Testing. J Clin Microbiol. 2021. PMID: 34105984. doi:10.1128/JCM.00791-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。